Seaport Therapeutics, Inc. (NASDAQ:SPTX) Receives $35.50 Consensus Target Price from Brokerages

Shares of Seaport Therapeutics, Inc. (NASDAQ:SPTX) have received a consensus recommendation of “Hold” from the nine brokerages that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $38.40.

A number of brokerages have issued reports on SPTX. Wolfe Research assumed coverage on Seaport Therapeutics in a research note on Tuesday, July 7th. They set a “hold” rating for the company. BNP Paribas Exane cut shares of Seaport Therapeutics to a “market perform” rating in a research report on Tuesday, May 26th. Wall Street Zen raised shares of Seaport Therapeutics to a “hold” rating in a report on Saturday, May 9th. HC Wainwright initiated coverage on shares of Seaport Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $50.00 price objective on the stock. Finally, Seaport Research Partners set a $50.00 target price on shares of Seaport Therapeutics in a report on Wednesday.

Seaport Therapeutics Price Performance

Shares of SPTX opened at $20.85 on Wednesday. The company has a market cap of $1.12 billion and a price-to-earnings ratio of -2.02. The firm has a 50-day moving average of $18.43. Seaport Therapeutics has a 52-week low of $14.85 and a 52-week high of $23.00.

Seaport Therapeutics (NASDAQ:SPTX) last issued its quarterly earnings results on Monday, June 8th. The company reported ($10.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($10.64) by $0.30.

Trending Headlines about Seaport Therapeutics

Here are the key news stories impacting Seaport Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Seaport Therapeutics and assigned a $50 price objective, implying substantial upside from current levels.
• Neutral Sentiment: The firm issued detailed earnings estimates for upcoming quarters and fiscal years, including expected losses of ($0.96) in Q2 2026, ($0.54) in Q3 2026, ($0.58) in Q4 2026, and ($3.25) for FY2026. Article Title
• Neutral Sentiment: HC Wainwright also forecast continued losses in 2027, with EPS estimates of ($0.61) for Q1, ($0.64) for Q2, ($0.66) for Q3, ($0.69) for Q4, and ($2.60) for FY2027.

Insiders Place Their Bets

In related news, major shareholder Arch Venture Partners Xii, Llc bought 1,100,000 shares of the business’s stock in a transaction dated Monday, May 4th. The shares were bought at an average cost of $18.00 per share, with a total value of $19,800,000.00. Following the completion of the transaction, the insider directly owned 6,294,951 shares of the company’s stock, valued at approximately $113,309,118. This trade represents a 21.17% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Robert J. Hombach purchased 13,000 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The stock was bought at an average price of $18.14 per share, with a total value of $235,820.00. Following the transaction, the director directly owned 13,000 shares in the company, valued at $235,820. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.